Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2006

View Archived Issues

Preclinical profile of PHA-680632 reported

AIM results detail abatacept efficacy in methotrexate-resistant rheumatoid arthritis

Lilly report on LY-2434074, a novel brain penetrating BACE1 inhibitor

Ixabepilone activity modest in patients with gastric cancer

Merck & Co. improves BACE1 inhibitor

Dainippon Sumitomo and Bristol-Myers enter into Japanese licensing agreements

TPM-02/Insulin studied in phase I trial

Treatment completed in phase I stem cell study of CB-001

Oscient to acquire Antara U.S. rights

Altus faces delays to initiation of phase III trials for ALTU-135 and ALTU-238

Accentia amends chronic sinusitis option agreement with Mayo Clinic

Nektar receives payment under Affymax partnership

Completion of phase IIa study of arimoclomol in ALS

Antares Pharma and Population Council to develop topical Nestorone product

Peptidomimetics derived from APP as a novel therapeutic strategy for AD

TG-C begins phase I trial for treatment of degenerative joint diseases

Sirion Therapeutics licenses U.S. rights to ophthalmic compound

RSD-1235 (oral) 300 mg shows trend towards efficacy in recurrent atrial fibrillation

AC-100 warrants further study for periodontal defects

Oncaspar approved in first-line treatment for ALL

Evoltra launched for ALL in U.K.

Novel C5a receptor inhibitor JPE-1375 improves allograft survival in mice

New CCR5 receptor antagonist from Incyte prevents cardiac allograft vasculopathy

Recent patents disclose novel antiinfective agents

Novel analgesic agents imparted in recent patent literature

Recent GSK patent describes novel diagnostic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...